A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up-Reference-Cited by-同舟云学术

A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up

Published:2020-07-01 Issue:6 Volume:30 Page:355-365
ISSN:1044-5463
Container-title:Journal of Child and Adolescent Psychopharmacology
language:en
Short-container-title:Journal of Child and Adolescent Psychopharmacology

Author:

Findling Robert L.¹,McCusker Emily²,Strawn Jeffrey R.³⁴

Affiliation:

1. Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, USA.

2. CNS, AbbVie, Irvine, California, USA.

3. Anxiety Disorders Research Program, University of Cincinnati, Cincinnati, Ohio, USA.

4. Department of Psychiatry & Behavioral Neuroscience, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Psychiatry and Mental health,Pediatrics, Perinatology, and Child Health

Link

https://www.liebertpub.com/doi/pdf/10.1089/cap.2019.0176

Reference44 articles.

1. A Double-Blind Efficacy and Safety Study of Duloxetine Flexible Dosing in Children and Adolescents with Major Depressive Disorder

2. Placebo Response in Randomized Controlled Trials of Antidepressants for Pediatric Major Depressive Disorder

3. Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressant Treatment

4. Predictors of Placebo Response in Randomized Controlled Trials of Psychotropic Drugs for Children and Adolescents with Internalizing Disorders

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7–17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies;Journal of Child and Adolescent Psychopharmacology;2024-06-01

2. VILAZODONE;Prescriber's Guide – Children and Adolescents;2024-05-02

3. The place of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depressive disorders in children and adolescents. Recommendations of the Main Board of the Polish Psychiatric Association. Part 2 – pharmacological properties and safety of use;Psychiatria Polska;2023-10-31

4. The place of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depressive disorders in children and adolescents. Recommendations of the Main Board of the Polish Psychiatric Association. Part 1 - Clinical efficacy and areas of application;Psychiatria Polska;2023-10-31

5. Sertraline versus escitalopram in South Asians with moderate to severe major depressive disorder: (SOUTH-DEP) a double-blind, parallel, randomized controlled trial;Annals of Medicine & Surgery;2023-09-05